Michael Nurok, Thoralf Sundt & Bruce Gewertz
In a value-based world, the sickest patients need the benefit of a comprehensive team to provide evidence-based treatment that will deliver desirable clinical outcomes while optimizing the cost of care.
Karen E. Joynt Maddox
Understanding APMs’ potential consequences for vulnerable populations is critical if we wish to maximize benefits and reduce harms.
Leemore Dafny, David Lansky, Robert Galvin & Lynn Garbee
The companies most capable of leading transformation in health care coverage are the ones that least need to.
Denis A. Cortese, Natalie Landman & Robert K. Smoldt
Given its clout and experience, CMS is uniquely positioned to lead the U.S. health system toward high-value care. Bundled pricing based on real costs, leveraging lessons from DRG implementation, would establish the right types of provider incentives.
Bob Kocher & Christopher J. Chen
Embracing two-sided risk while adopting workflow redesign and reviewing benchmarks is leading to improved clinical and financial outcomes.
David Lansky, Robert Galvin, Lynn Garbee & Leemore Dafny
Why are employers hesitating? What do they value and want to invest in when it comes to health care payment plans?
The CEO of Virginia Mason on facilitating and enhancing patient participation in care.
NEJM Catalyst Insights Council members say stronger incentives and better use of analytics could improve alignment.
Although the transition from fee-for-service to quality-based payment can leave physicians feeling trapped “with a foot in two canoes” while straddling the two payment methods, there are compelling ethical, professional, and business reasons against rationalizing continued support of fee-for-service medicine.
What impact do market exclusivity periods have on the cost of drugs and on incentives for innovation?